Supplemental Information

3 Months Ended

Mar. 31, 2020

Geographic Areas, Long-Lived Assets [Abstract]

SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:


	March 31, 2020		December 31, 2019
	Unaudited		Audited
United States	$	9,562	$	8,896
Switzerland	2,472		3,067
Israel	3,366		2,753
Germany	711		729
Others	2,134		1,581
Total long-term assets	$	18,245	$	17,026

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:


	Three months ended March 31,						Year ended December 31, 2019
	2020		2019
	Unaudited						Audited
United States	$	69,259	$	46,604	$	232,805
EMEA:
Germany	21,802		20,238		86,564
Other EMEA	2,674		2,282		8,782
Japan	6,451		3,370		17,912
Greater China (1)	1,642		815		5,255
Total net revenues	$	101,828	$	73,309	$	351,318

(1) Reflects revenue recognized in accordance with a License and Collaboration Agreement (the "Zai Agreement") between us and Zai Lab (Shanghai) Co., Ltd. (“Zai”), dated September 10, 2018, pursuant to which Zai is commercializing Optune in China, Hong Kong, Macau and Taiwan (referred to in this table as “Greater China”) and also includes $90 recognized during the three months ended March 31, 2020 from reaching a clinical trial milestone during the period. The full amount of the milestone payable is $2,000 that will be recognized over the remainder of the Zai performance period ending in September 2024. For additional information, see Note 12 to the Consolidated Financial Statements in our 2019 10-K.